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Abstract
Background: The recurrence rate of periocular nodular basal cell carcinoma (PNBCC) following treatment with
imiquimod (IMQ) has not yet been established. Previous studies did not include histological follow-up. The aim of
this analysis was to evaluate the efficacy of topical immunotherapy with 5% IMQ cream for the treatment of PNBCC.
Methods: Study design: A prospective, non-randomized, and uncontrolled longitudinal case series study. No
participants were blinded. Punch biopsy confirmed PNBCC patients were included at the Ophthalmology Clinic of
São Paulo University Medicine School Hospital (from 2008 to 2012). Patients were treated with 5% IMQ cream once
a day, 5 days per week, for 8–16 weeks. Standard lesion photographic documentation was done during the study.
Three months after treatment ended, an image-guided biopsy was performed. Patients were followed at 6-month
intervals and annually for control biopsies. Main outcome measures were clinical and histological clearance rates.
Data were analysed by frequency distribution for qualitative group characteristics and central tendency measures
for quantitative data.
Results: Twenty-four patients met the inclusion criteria, 19 of whom remained until the end of treatment. The
histological clearance rate was 89.5% and 84.2%, respectively, at 3 and 39.5 months. The 3-year histological
clearance rate was 81.8% (9/11) for lesions >10 mm, and 100% (8/8) for lesions <10 mm. Three patients did not
tolerate the side effects of the medication and left the study. Two patients were excluded for treatment interruption
related to comorbidities.
Conclusions: Our results indicated that 5% IMQ cream was a useful alternative treatment for NBBCC, especially for
lesions <10 mm. IMQ also showed a significant neoadjuvant effect on lesions >10 mm.
Trial registration: ClinicalTrial.gov Registration Dec 3, 2008: #NCT 00803907.
Keywords: Basal cell carcinoma, Periocular neoplasm/therapy, Antineoplastic drug, Immunotherapy, Topical
administration
Background
The incidence of basal cell carcinoma (BCC), the most
common human neoplasm, has increased significantly
worldwide over the past few years [1,2]. More than 80% of
BCCs affected the neck and face, 20% of which were in
the form of periocular tumours [3]. It was estimated that
30–40% of patients with BCC would develop one or more
new lesions over the next 10 years [4].
BCC is the main cause of required reconstructive sur-
gery in the periocular region. For facial BCC, Mohs sur-
gery is considered the method with the best chance of
cure, with 5-year recurrence rates of up to 6.5% [5].
Nodular BCC, the most common subtype in eyelids, has
a surgical cure rate of 85–95% [6].
For cases in which surgery is not possible (multiple le-
sions, high surgical risk, and refusal of surgery), topical im-
munotherapy may be an alternative. Imiquimod (IMQ), an
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immune modulator, acts by stimulating innate and adap-
tive immunity and by inducing apoptosis in tumour cells
[2]. The ideal mode of administration of IMQ remains
uncertain. The drug has been applied once or twice per
day or 3–7 times a week during 6–16 weeks with vari-
able results [7,8].
IMQ use, as an alternative treatment for periocular
BCC, was suggested using results from a small case series
with an almost 100% reported cure rate [9-11]. However,
no histological follow-up was provided in these studies.
Leppala et al. [12] and Garcia-Martin et al. [13], however,
demonstrated short-term (3 months) biopsy documen-
tation after treatments. For periocular NBCC (PNBCC),
Eigentler et al. showed residual tumours in one third of
patients given IMQ three times per week for 8–12
weeks [8].
The purpose of the present study was therefore to
evaluate clinically and histologically the effects of 5%
topical IMQ cream on PNBCC by evaluating for residual
tumour rate and recurrence.
Methods
This was an interventional prospective, non-randomized,
and uncontrolled longitudinal case series study, con-
ducted between 2008 and 2012. The study followed the
tenets of the Declaration of Helsinki, and was approved
by the University of São Paulo Medical School Hospital
Institutional Review Board Ethics Committee. All partic-
ipants gave their informed consent. The ClinicalTrial.gov
number was NCT00803907.
Patients with periocular biopsy diagnosed as NBCC
were included in this study. We limited eyelid margin
lesions up to 20 mm, and medial canthus lesions up to
30 mm (largest diameter), with no infiltrating deeper tis-
sues on palpation. All lesions had not had prior treat-
ment. Recurrent BCC lesions and patients with clinical
signs of orbit invasion were excluded. Uncooperative pa-
tients with no caregiver assistance to correctly apply the
medication were also excluded.
Main outcome measures were clinical and histological
clearance rates. To detect a histological tumour clearance
rate of 50% at 3 months, with a 5% significance level and
95% confidence, a sample size of 22 patients was necessary,
given an anticipated dropout rate of 10% (http://www.nss.
gov.au/nss/home.nsf/). All patients were submitted to IMQ
cream treatment. No participants were blinded.
IMQ cream (Aldara®; Meda AB, Graceway Pharmaceuti-
cals, Bristol, TN, USA) was applied once each day at bed-
time. To ensure patient safety, we instructed patients and
caregivers (or relatives) to use lubricating gel in the con-
junctival sac before IMQ cream application. We stressed
the correct medication application, using a swab, and tak-
ing care to keep the border of the eyelid away from the
eye. The cream remained in contact with the tumour for 8
to 10 hours. In the morning, the periocular area was
washed with neutral liquid soap. In cases of accidental
contact with the ocular surface and conjunctiva, the pa-
tient was instructed to wash abundantly with saline solu-
tion and apply lubricating eye gel.
Artificial tears were prescribed and provided free of
charge to the patients, for application every 6 hours dur-
ing the day. IMQ was used once each day, 5 days a week,
for a minimum of 8 weeks and a maximum of 16 weeks.
Within this period, treatment was discontinued once the
lesion became undetectable by slit lamp examination
and palpation.
During the treatment period, patients were followed
biweekly and information was collected through ques-
tionnaires, slit lamp examinations, visual acuity testing,
photography, and measurement of lesions, using Image J
software (version 1.42) [14].
Baseline measurements were obtained from photographs
taken after the initial biopsy so that the amount of tissue
removed would not influence the results. The final mea-
surements were based on photographs taken 3 months
(12 weeks) after treatment end.
We used 2-mm trephine for all biopsies. An image-
guided biopsy of the region was performed 3 months
(12 weeks) after treatment. Patients with clinical or histo-
logical findings of residual lesions were referred for surgi-
cal excision and reconstruction. Patients were followed at
6-month intervals, with annual control biopsies.
Data were analysed by frequency distribution for quali-
tative group characteristics and central tendency measures
for quantitative data.
Results
Throughout the study, 24 patients met the inclusion cri-
teria, 19 of whom remained until the end of treatment.
Patients were recruited until December 2012 when the
required sample size was obtained. Three patients did
not tolerate the side effects of the medication and left
the study. One patient suffered an ischemic cerebrovas-
cular accident, and one patient died during the treat-
ment period. Both cases were associated with previous
diseases and high surgical risk (Figure 1).
One patient (case 12) interrupted treatment for 2 weeks
because of intense local inflammation associated with sys-
temic symptoms. This patient was also the only patient
who experienced tumour recurrence, as confirmed by bi-
opsy 2 years after treatment (Figure 2).
Seventeen patients had complete clinical clearance at
the 3-month evaluation (Table 1). Two patients had a
residual tumour (Table 2). Punch biopsy showed a his-
tologically tumour-free rate of 89.5% at 3 months and
84.2% by the end of follow-up (39.5 months) (Table 1).
Two cases with successful outcomes are shown in
Figure 3.
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Assessed for eligibility (n=24 ) 
Excluded  (n=5 ) 
♦ Declined after side effects (n=3 ) 
♦ Other reasons (n=2  ) 
Analysed  (n=16) 
Clinical clearance (n=17) 
Histological clearance (n=16) 
 Clinical clearance (n=17)
Surgery (n=2) 
Residual lesion (n= 2)




 n=19  
Enrollment
Figure 1 Imiquimod (IMQ) treatment flow chart.
Figure 2 Lesion #12. Nodular basal cell carcinoma in the medial canthus. A) before treatment, B) local inflammation mimicking preseptal
cellulitis, C) 2 years after treatment completion, when the biopsy identified BCC recurrence.
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The most frequent ocular symptoms and signs were
conjunctivitis (95%), followed by keratitis (84%), foreign
body sensation (79%), lacrimation (58%), low visual acu-
ity (53%), and ectropion (37%). Treatment consisted of
frequent lubrication with eye drops. All patients presented
with some degree of skin reaction such as hyperaemia,
crusting, ulceration, and bleeding during treatment. No
medication was prescribed except for cold compresses. No
side effects were permanent and all were resolved after
the end of treatment.
Discussion
The current investigation confirmed several previous
studies reporting favourable results with IMQ [12,13] and
suggested that IMQ played an important role in the man-
agement of PNBCC as an alternative non-surgical treat-
ment. The present study proposed treatment once per
day, five times per week for 8 to 16 weeks. Treatment time
depended on healing of skin and absence of tumours at
slit lamp examination, and on palpation, therefore treat-
ment lasted 12.6 weeks on average. Histological clearance
was 89.5% (17/19) by the end of the treatment, and 84.2%
(16/19) after 3 years of follow-up (Table 2).
Previous PNBCC studies reported treatments lasting
6 weeks, at seven applications per week and with 71%
efficacy, and 50–59% efficacy with three applications
[15,16]. However, three applications per week for 8 weeks
yielded an efficacy of 64% [8]. The highest cure rates re-
ported were observed with treatment for 12 weeks as fol-
lows: 60–63% efficacy with three applications per week,
70% efficacy with five applications per week, and 76% effi-
cacy with seven applications per week [8,16].
In the present study, 57.9% (11/19) of the patients had
lesions >10 mm. Interestingly, the 3-year histological
clearance rate was 81.8% (9/11) for lesions >10 mm, and
100% (8/8) for lesions <10 mm. Eigentler et al. obtained
the best results in smaller lesions (72% cure rate for
smaller lesions versus 48% for larger lesions), and ob-
served that the larger the tumour, the less efficacious the
medication and the longer the required treatment [8].
Thus, a treatment duration of 6 weeks was reported to
be a negative prognostic factor in the treatment of perio-
cular lesions larger than 10 mm [13]. This finding was
supported by the association between tumour profile
(percentage of tumours greater than 10 mm and mean
and median lesion size) and different dosage regimens
used in six studies evaluating treatment of PNBCC with
5% IMQ cream (Table 3) [9-13,17]. Partial resolution
(tumours were reduced but did not disappear completely,
producing a neoadjuvant effect) was more commonly ob-
served with nodular lesions when compared with superfi-
cial BCC [18].
Only two of our patients had partial tumour clearance.
Both had lesions larger than 10 mm, and in both cases the
medication had a neoadjuvant effect, significantly reducing
tumour size and thereby facilitating surgery (Table 1). The
less healthy the tissue removed in surgery, the smaller the risk
of compromising eyelid function and aesthetics. The main
complications of surgical excision of large amounts of perio-
cular tissue included scarring, palpebral retraction, trichiasis,
ptosis, chronic epiphora, entropion, ectropion, keratitis, and
corneal ulcer caused by exposure or perforation [19].
At baseline, lesion 1 (lower eyelid margin) measured
13.5 mm. Adding a 2-mm safety margin on each side, an
area equivalent to half the eyelid (17.5 mm), would
have required reconstruction of the eyelid. After treat-
ment with 5% IMQ cream, the diameter was reduced to
4.2 mm. Including the safety margin, the area to be
reconstructed (8.2 mm) was less than one third the size
of the eyelid. In this patient the safety margins were
free and the lesion was submitted to pentagonal exci-
sion, cantholysis, and closure.
Lesion 8 (medial canthus) was reduced from 27.2 mm
to 7.6 mm. Thus, instead of performing a complex
surgery with glabellar flap rotation and advancement,
the patient was submitted to simple excision and direct
closure of the tumour-free surgical margins.
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The patient with lesion 12 interrupted the treatment
for 2 weeks because of intense local inflammation mim-
icking preseptal cellulitis, but systemic symptoms were
also observed, especially diarrhoea. The interruption may
have influenced the evolution because this was the only
patient with recurrence of BCC (Figure 1). There was evi-
dence that recurrence of superficial BCC was low after
treatment with IMQ and that the resolution rate remained
high during 5 years of clinical follow-up. The clinical and
histological outcome 12 weeks after treatment appeared
to be a reliable predictor of the risk of recurrence, which
was most commonly observed during the first year of
follow-up [20].
Bath-Hextall et al. recently reported a large randomized
trial with 3 years of follow-up comparing IMQ and sur-
gery in nodular and superficial BCC, showing a recurrence
rate of 18.3%. However, this study did not include periocu-
lar regions [21]. The recurrence rate of PNBCC following
treatment with IMQ has not yet been established. Studies
with a larger series of BCC patients have focused on
short-term elimination of tumours rather than on the
observation of recurrence. We identified only one study
with a long enough follow-up time to detect recurrence,
a study of four patients with BCC in the periocular area,
followed up for 7 years [11]. Two studies performed
biopsy at 3 months [12,13]. Because PNBCC is more
complex and more established than superficial BCC,
late recurrence without clinical signs is a possibility, and
was observed for lesion 12 (Figure 1–C), which recurred
after 2 years.
Our study was the largest IMQ-treated PNBCC pa-
tient series with histological follow-up beyond 3 years.
Follow-up for recurrence was based on clinical exami-
nations and histological controls. Excisional biopsy of
whole compromised areas would be desirable but not
feasible to perform every year. The 2-mm punch biopsy
used here was a swift and simple diagnostic technique
with a high level of agreement compared with analysis
of whole surgical specimens (90% accuracy for malig-
nancy diagnosis) [22].
Despite longer treatment, our patients had only minor
ocular symptoms (conjunctivitis, keratitis, and foreign body
sensation) and no permanent eye damage was observed.
Cannon et al., in a retrospective study, described conjunctiv-
itis and eye burning sensation as the most common symp-
toms during treatment of periocular lesions, despite the fact
that only three in a sample of 47 patients had periocular
BCC, and IMQ was administered three times per week for
4–6 weeks [23]. All symptoms caused by the medication
were transient and resolved after ending treatment.
The main limitation of the present study was the lack
of a comparative group (such as a surgical group).
Regarding generalization to other cases, our cases con-
sisted of primary PNBCC lesions without signs of deep
infiltration or orbit invasion, therefore it was a limited
group of patients.
Table 2 Description of 19 patients with confirmed periocular basal cell carcinoma treated with 5% imiquimod cream
Lesion †Area (mm2) †Largest diameter (mm) ‡Residual area (mm2) ‡Largest residual diameter (mm) Treatment time (weeks)
1 131.97 12.01 13.53 4.25 8
2 108.18 11.70 0 0 12
3 64.56 10.63 0 0 16
4 67.09 11.65 0 0 12
5 53.34 15.03 0 0 12
6 20.76 5.10 0 0 8
7 32.32 7.51 0 0 10
8 165.38 27.18 22.07 7.63 12
9 189.14 17.96 0 0 12
10 18.53 5.06 0 0 14
11 15.99 2.77 0 0 12
12 121.01 15.66 0 0 16
13 35.53 9.46 0 0 14
14 45.32 16.01 0 0 12
15 4.36 2.82 0 0 12
16 39.83 10.29 0 0 14
17 121.27 15.45 0 0 16
18 60.63 8.70 0 0 16
19 32.18 5.38 0 0 12
†Before treatment, ‡3 months after treatment completion.
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Although surgical excision remains the gold standard
for PNBCC and is associated with the highest cure rates
[24], in the present study IMQ was shown to be an effica-
cious and safe alternative treatment. However, we stress
the importance of careful follow-up even after clinical
clearance to manage recurrence cases.
Conclusions
The recurrence rate of periocular nodular basal cell carcinoma
(BCC) following treatment with IMQ was low. The 3-year
histological clearance rate was 100% (8/8) for lesions <10 mm
and 81.8% (9/11) for lesions >10 mm. Importantly, IMQ had
significant neoadjuvant effects on PNBCC lesions >10mm.
Table 3 Comparison of results evaluating imiquimod treatment of periocular nodular basal cell carcinoma










Present study 19 5/wk 11.1 (6.0) 58 84.2 3.3 36
8–16 wk
Prokosch 2011 [11] 4 5/wk 11.5 (4.5) 50 100 7.0 -
6 wk
Garcia-Martin 2010 [13] 15 5/wk 7.6 (2.9) 25 100 2.0 3
6 wk
Carneiro 2010 [22] 10 5/wk 12.1 (6.5) 60 80 1.0 12
10–16 wk
Choontanom 2007 [10] 5 5/wk 10.8 (4.2) 40 80 3.0 -
6 wk
Leppälä 2007 [12] 4 5/wk 8.5 (4.6) 25 100 0.5 3
6 wk
Blasi 2005 [9] 2 3/wk - - 100 1.0 -
8–12 wk
SD = standard deviation; wk = weeks.
Figure 3 Clinical pictures before and 3 years after treatment. A) Case #13: Eyelid margin PNBCC, B) after treatment, C) case #4, medial
canthus PNBCC, D) after treatment.
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